UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of December 2025
Commission File Number: 001-42484
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of Registrant’s name into
English)
68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
On December 6, 2025, Ascentage
Pharma Group International issued a press release entitled “Ascentage Pharma Presents Pivotal China Registrational Study Data for
Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting”. A copy of the press release is furnished
as Exhibit 99.1 to this Report. On December 8, 2025, Ascentage Pharma Group International issued a press release entitled “ASH 2025 | Ascentage
Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid
Malignances”. A copy fo the press release is furnished as Exhibit 99.2 to this Report.
INDEX TO EXHIBITS
| Exhibit |
|
|
| Number |
|
Exhibit Title |
| |
|
|
| 99.1 |
|
Press Release dated December 6, 2025 |
| 99.2 |
|
Press Release dated December 8, 2025 |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
ASCENTAGE PHARMA GROUP INTERNATIONAL |
| |
|
| Date: December 8, 2025 |
/s/ Dajun Yang |
| |
Name: |
Dajun Yang |
| |
Title: |
Chief Executive Officer |
3
